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Abstract: Three new series of paracyclophanyl-dihydronaphtho[2,3-d]thiazoles and 
paracyclophanyl-thiazolium bromides were designed, synthesized, and characterized by their 
spectroscopic data, along with X-ray analysis. One-dose assay results of anticancer activity 
indicated that 3a–e had the highest ability to inhibit the proliferation of different cancer cell lines. 
Moreover, the hybrids 3c–e were selected for five-dose analyses to demonstrate a broad spectrum 
of antitumor activity without apparent selectivity. Interestingly, series I compounds (Z)-N-
substituted-4,9-dihydronaphtho[2,3-d]thiazol-3(2H)-yl)-4’-[2.2]paracyclophanylamide) that are 
carrying 1,4-dihydronaphthoquinone were more active as antiproliferative agents than their 
naphthalene-containing congeners (series II: substituted 2-(4’-[2.2]paracyclophanyl)hydrazinyl)-4-
(naphth-2-yl)-thiazol-3-ium bromide hybrids) and (series III: 3-(4’-[2.2]paracyclophanyl)amido-2-
(cyclopropylamino)-4-(naphth-2-yl)thiazol-3-ium bromide) toward the SK-MEL-5 melanoma cell 
line. Further antiproliferation investigations of 3c and 3e on the healthy, normal unaffected SK-
MEL-5 cell line indicated their relative safety. Compound 3c showed an inhibition of eight 
isoforms of cyclin-dependent kinases (CDK); however, it exhibited the lowest IC50 of 54.8 nM on 
CDK1 in comparison to Dinaciclib as a reference. Additionally, compound 3c revealed a 
remarkable downregulation of phospho-Tyr15 with a level (7.45 pg/mL) close to the reference. 3c 
mainly showed cell cycle arrest in the pre-G1 and G2/M phases upon analysis of the SK-MEL-5 cell 
line. The sequential caspase-3 assay for 3c indicated a remarkable overexpression level. Finally, a 
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molecular docking study was adopted to elucidate the binding mode and interactions of the target 
compounds with CDK1. 
Keywords: paracyclophane; thiazole; apoptosis; CDK1; 1,4-naphthoquinone; antitumor; 
melanoma; molecular docking 
 
1. Introduction 
1,4-Naphthoquinones are an important scaffold common in the structure of various natural 
products [1–5], and are present in synthetic compounds that exert diverse biological and 
pharmaceutical applications [6]. 1,4-Naphthoquinone derivatives are used as antibacterial [7], 
antifungal [8], and antitumor agents [9]. The chemistry of quinone-annulated heterocycles is highly 
dependent on the substituents at the quinone showing potent antitumor activity, such as 
daunorubicin (I) and mitoxantrone (II) (Figure 1) [10,11]. Pterocaryquinone was isolated from 
Pterocarya tonkinesis and showed activity toward mouth cancer [12]. In searching for agents with 
better pharmacological properties, a wider reactivity range, and low side effects, it seemed quite 
promising to incorporate a heterocyclic ring with two heteroatoms (e.g., thiazole) [13]. The thiazole 
scaffold incorporated in variant therapeutic agents, such as compounds III, IV, and B (Figure 1), 
has been widely investigated for its antitumor biological effects [14,15], and it was reported that it 
exhibits antiproliferative activity against different human tumor cell lines, with GI50 in the range 
0.03–2.38 μM [16]. Additionally, it confined viable cells in the G2/M phase and markedly inhibited 
the in vitro CDK1 activity [16]. Deregulation of the cell cycle is one of the hallmarks of tumor 
formation and progression [17]. Human kinases remain interesting targets in oncology; cyclin-
dependent kinases (CDKs) are a class of serine/threonine-protein kinases that regulates the 
temporal progression of cells through the cell cycle [18]. To date, 21 different CDKs (1−11a and 
11b−20) have been identified in the human genome, and they can be classified into two main 
categories based on their primary roles [19,20]. CDK1, CDK2, CDK4, and CDK6 have been 
discovered to regulate the cell cycle progression upon binding to cyclin proteins. CDK1 forms a 
complex with cyclin A/B and regulates the phosphorylation of cytoskeleton proteins involved in 
mitosis [15]. CDK1 is a potential therapeutic target using novel selective small molecule inhibitors 
of CDK1 [15]. 
The maturation of the synthetic methodologies for paracyclophanes (PC), with the possibilities 
for the fine-tuning of structural and functional properties, [2.2]paracyclophane (PC) chemistry has 
evolved as an interesting class of functional materials [21–23]. Aly et al. synthesized heterocycles 
conjugated to [2.2]paracyclophane, such as a five-membered ring (i.e., imidazolinone and pyrrole) 
[24,25] and a six-membered ring (i.e., pyridine) [26,27]. Additionally, his group reported on the 
synthesis of various paracyclophanyl-substituted thiosemicarbazones, thiocarbazones, and 
thioureas, then studied their complexation towards tridentate and bidentate copper complexes 
[28,29]. A series of naphthothiazoldiones were synthesized by the reaction of N-substituted 
thioureas with 2,3-dichloro-1,4-naphthoquinone [30,31]. Moreover, naphthothiazole-5-
carboxamides were obtained from naphthalimides [32], as well as N-substituted-2-
(methylamino)naphthoquinones that reacted with S2Cl2 and DABCO (1,4-diazobicyclooctane) to 
give 2,3-dihydronaphtho[2,3-d][1,3]thiazole-4,9-diones [33]. Despite continuous interest in 1,4-
naphthoquinones fused with heterocycles, only a limited number of naphthoquinothiadiazines 
have been known so far. One of the most important methods in carbon–carbon bond formation is 
the Eschenmoser-coupling reaction [34]. The reaction of thioamides with mono-haloketones and the 
preparation of several heterocyclic rings, as well as natural products via the Eschenmoser method, 
has been also reported [35]. 
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Figure 1. Reported antitumor 1,4-naphthoquinones, thiazoles, and [2.2]paracyclophane derivatives 
(I–IV), along with benzylic-thiazoles A and paracyclophanylthiazole B and the new designed 
compounds: series I (3a–e), series II (8a–d), and series III (9). CDK: cyclin-dependent kinases. 
Compound Design Rationale 
Enlightened by the aforementioned information, and in continuation of our efforts in probing 
for novel effective anticancer agents, we designed and synthesized three series of novel 
thiazole/paracyclophane conjugates (Figure 1) and investigation them as new CDK1 inhibitors. 
Series I was designed to fuse a naphthoquinone moiety with the thiazole ring to explore more 
binding with the target enzyme, whereas series II and III bore a naphthyl moiety attached to 
thiazole with variant substitutions at N-thiazole (series II) or position 2 of thiazole (series III). The 
introduction of different substitutions for the three synthesized series was considered of interest to 
be a more suitable molecular skeleton aiming at varying the physicochemical properties of the 
molecules and allowing for a structure–activity relationship exploration study (Figure 1). 
It has been demonstrated that the presence of a substituted benzyl ring (i.e., 4-fluoro-, 3,4-
dichloro, or 4-methyl) at position 4 of the thiazole compounds increases the critical maximum 
anticancer activity of the thiazole molecules A [36], since the [2.2]paracyclophane molecule has two 
benzylic moieties and, accordingly, the products can be expected to have increased antitumor cell 
activity of the obtained products. An increased effect of the [2.2]paracyclophane moiety on the 
anticancer activity was reported with a series of methyl 2-(2-(4’-[2.2]paracyclophanyl)-
hydrazinylidene)-3-substituted-4-oxothiazolidin-5-ylidene)acetates B (Figure 1) [37]. It has been 
reported that the ring composition of drugs containing aromatic rings in proportion to drugs 
containing one (or two or three or more) aromatic rings in all drugs possessing aromatic rings were 
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elaborately analyzed [38]. The results indicate that, among the drugs possessing aromatic rings, 
most of the drugs having one/two aromatic rings (all drugs: 79.9%, oral drugs: 78.5%, central 
nervous system drugs: 86.4%, cardiovascular drugs: 78.9%, and anti-infective drugs: 81.9%), except 
the anticancer drugs (59.8%) [38]. The statistical results also indicate that candidate drugs with less 
than four aromatic rings (optimally, one or two, except anticancer drugs, which also tolerate up to 
three aromatic rings) may possess good drug-like properties and be likely to be developed into 
approved drugs [38]. Moreover, the p-xylene derivative is considered as a half in its structure to 
[2.2]paracyclophane, so that molecular docking calculations might help to make a comparison. 
Taking into consideration that the [2.2]paracyclophane moiety has been known by its transannular 
electronic interaction between its rings [39], however, which was not found in p-xylene. 
Accordingly, to investigate the possible antitumor mechanisms of the synthesized paracyclophanyl-
dihydronaphthoquinone[2,3-d]thiazoles, CDK1, and other kinases, an enzymatic assay was 
performed. Docking calculations inside the active site of the CDK1 enzyme were done. A cell cycle 
analysis and apoptosis through the caspase-3 expression level were screened. 
2. Results and Discussion 
2.1. Chemistry 
On reacting compounds 1a–e [40] with 2,3-dichloro-1,4-naphthoquinone (2) under the 
Eschenmoser contraction condition (Ph3P, Et3N, and CH3CN) under reflux, the reaction proceeded 
to give fused thiazoles 3a–e in 55–70% yield (Scheme 1). 
 
Scheme 1. The reaction of 1a–f with 2 under the Eschenmoser condition; synthesis of fused thiazoles 
3a–e. 
The structure of the obtained products of 3a–e was confirmed by IR, NMR, and mass spectra, 
in addition to an elemental analysis. For example, compound 3e was obtained as red crystals in 55% 
yield. Both the mass spectroscopy and elemental analysis confirmed the molecular formula of 3e as 
C31H25O3N3S. The 1H NMR spectrum showed one singlet at δ = 10.12 (amide-NH) and the 
cyclopropyl protons as three multiplets at δ = 2.58–2.54 (1H), 1.72–1.74 (1H), 1.20-0.47 ppm (3H). 
The 13C NMR spectrum revealed some distinctive carbon signals at δ = 179.4, 176.8 
(naphthoquinone-CO), 173.6 (amide-CO), 167.8 (thiazole-C-2), 26.0 (cyclopropyl-CH), 7.9 
(cyclopropyl-CH2), and 7.5 ppm (cyclopropyl-CH2). The X-ray structure analysis confirmed the 
structure of 3e, as shown in Figure 2. 
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Figure 2. Molecular structure of compound 3e identified according to IUPAC nomenclature as (Z)-
N-(2-(cyclopropylimino)-4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-3(2H)-yl)-1,4(1,4)-dibenzo-
cyclohexaphane-12-carboxamide. 
The mechanism would be an initial formation of Zwitter ion salt 4. Thereafter, a sulfur lone 
pair in 1a–e would attack the positive carbon in 4, which would eliminate a molecule of Ph3P to 
give intermediate 5 (Scheme 2). The neutralization and elimination of one molecule of HCl would 
then initiate by the presence of Et3N to give intermediate 6. Repeating the previous process by the 
attachment of a molecule of Ph3P and elimination of the second molecule of HCl initiated by Et3N 
would give compounds 3a–e (Scheme 2). 
 
Scheme 2. Mechanism describes the formation of compounds 3a-e under the Eschenmoser 
contraction condition. 
Synthesis of Substituted Thiazoles 8a–d and 9 
On reacting compounds 1a–e with 2-bromo-1-(naphth-1-yl)ethanone (7) in ethyl acetate and at 
room temperature, the reaction proceeded to give compounds 8a–d with the corresponding 
derivatives of 1a–d. On the other hand, the reaction of compound 1e with 7 gave the regioisomer 9 
in 60% yield (Scheme 3). 
In the case of compound 8c, the 1H NMR spectrum showed three singlets at δ = 11.23, 7.35, and 
6.95 ppm corresponding to amide-NH, thiazole-CH-5, and hydrazinyl-NH, respectively. The allyl 
protons resonated as three multiplets at δ = 5.89–5.80, 5.32–5.00, and 4.84–4.70 ppm for allyl-CH=, 
allyl-CH2=, and allyl-CH2-, respectively (see the Experimental section). The 13C NMR spectrum 
confirmed the structure of 8c by the appearance of carbon signals at δ = 173.8 (amide-CO), 168.2 
(thiazole-C-2), 143.4 (thiazole-C4), 133.5 (allyl-CH=), 118.9 (allyl-CH2=), 108.3 (thiazole-CH-5), and 
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50.4 ppm (allyl-CH2). The structure of 8c was confirmed by the X-ray structure analysis, as shown in 
Figure 3. 
 
Scheme 3. The reaction of 1a–e with 7; the synthesis of thiazole derivatives 8a–d and 9. 
 
Figure 3. Molecular structure of the dimer of compound 8c identified according to IUPAC 
nomenclature as the 2-(2-(1,4[1,4]-dibenzenacyclohexaphane-12-carbonyl)hydrazinyl)-3-allyl-4-
(naphth-2-yl)thiazol-3-ium bromide. 
In compound 9, the 1H NMR spectrum revealed three singlets at δ = 11.79, 7.47, and 5.36 
related to amide-NH, thiazole-CH, and NH-amine, respectively. The cyclopropyl protons resonated 
as three multiplets at δ = 2.74–2.64 (1H), 1.04–0.95 (cyclopropyl-CH2), and 0.81–0.75 (cyclopropyl-
CH2). The 13C NMR spectrum showed the carbon signals of CO-amide, thiazole-C-2, thiazole-C-4, 
and thiazole-CH-5 at δ = 172.0, 166.1, 142.4, and 104.3 ppm, respectively. The cyclopropyl protons 
resonated at δ = 28.2 (cyclopropyl-CH), 7.3 (cyclopropyl-CH2), and 7.2 ppm (cyclopropyl-CH2). The 
structure of compound 9 was confirmed by the X-ray structure analysis, as shown in Figure 4. 
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Figure 4. Molecular structure of compound 9 identified according to IUPAC nomenclature as 3-
(1,4(1,4)-dibenzenacyclohexaphane-12-carboxamido)-2-(cyclopropylamino)-4-(naphth-2-yl)thiazol-3-
ium bromide. 
The mechanism that describes the formation of 8a–d (Scheme 4) depends on an initial addition 
of the sulfur lone pair to the electrophilic carbon of 7 to produce Zwitter ion salt 10. The elimination 
of a molecule of HBr from intermediate 10 would give 11. Two routes were then proposed as routes 
(a) in which the cyclization process occurred from the amine-NH to the carbonyl carbon to give salt 
12. The neutralization of 12 would give intermediate 13 (Scheme 4). The elimination of water from 
13 would give 14, which stabilized by abstracting the liberating HBr to form products 8a–d (Scheme 
4). Route (b) describes the other type of cyclization process that occurred to intermediate 11 by the 
hydrazinyl-NH lone pair. On repeating the previously mentioned steps, compound 9 would be 
formed (Scheme 4). 
 
Scheme 4. Mechanism describes the formation of compounds 8a–d and 9. 
2.2. Biological Activity Evaluation 
2.2.1. In Vitro Screening of One-Dose Anticancer Activity on 60 Cancer Cell Lines 
Among the synthesized compounds, 3a–e and 8a–d were chosen by the National Cancer 
Institute (NCI) according to the protocol of the Drug Evaluation Branch of the National Cancer 
Institute, Bethesda, MD, USA for the in vitro anticancer screening on 60 cancer cell lines. The 
methodology of the NCI anticancer screening has been described in detail elsewhere 
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(http://www.dtp.nci.nih.gov). Tested compounds were added to the culture at a single 
concentration (10−5 M), and the cultures were incubated for 48 h. Endpoint determinations were 
made with a protein-binding dye, sulforodamine B (SRB). The results for each tested compound 
were reported as the percentage of growth of the treated cells when compared to the untreated 
control cells. The percentage of growth was evaluated spectrophotometrically versus controls not 
treated with test agents. All experiments were repeated three times. The NCI results of the 
naphthothiazole/paracyclophane conjugates recorded in Table 1 indicate that five compounds 3a–e 
displayed very potent anticancer activity with complete cell death (% of growth inhibition ≥ 100%) 
on most of the tested cancer cell lines. Interestingly, compounds 3c and 3d showed complete cell 
death on all nine cancer cell panels in a range of 103.65–198.49% and 103.66–197.05%, respectively. 
Additionally, compound 3e showed complete cell death on three cancer cell panels (colon cancer, 
CNS cancer, and melanoma) of the range 109.10–193.24%. Compounds 3a and 3b, as well as 8c, had 
complete cell death on only one panel (melanoma) of the range 110.14–172.49%, while they 
exhibited moderate cytotoxic activity toward the other tested cell lines. On the other hand, 
compounds 8a, 8b, and 8d possessed lesser activity. Compound 8d had significant cytotoxicity 
against melanoma SK-MEL-5 and breast cancer T-47D, with inhibition % of 83.18% and 75.60%, 
respectively. However, it showed moderate activity against leukemia RPMI-8226 and colon cancer 
HCT-15, with cell growth inhibition (%) of 62.22% and 59.89%, respectively. Moreover, compound 
8b had moderate inhibition against leukemia K-562, colon cancer HCT-15, and prostate cancer PC-3, 
with an inhibition percent of 54.53%, 63.36%, and 54.49%, respectively. Meanwhile, compound 8a 
displayed weak cell growth inhibition activity against most of the tested cancer cell lines. 
Regarding the results recorded in Table 1, it can be deduced that the replacement of the 
naphthyl group by the naphthoquinone group, as in compounds 3a–e, gave the fascinating 
outstanding anticancer activity on the tested cancer cell lines. This could be attributed to increasing 
the binding to the target protein due to the presence of an extra two oxygen groups in the quinone 
moiety, and this encouraged us to further test them throughout the molecular docking study. 
Table 1. Growth percent of compounds 3a–e and 8a–d (at conc. 10−5 M) against different cell lines. 
Panel/Cell Line 3a 3b 3c 3d 3e 8a 8b 8c 8d 
Leukemia 
CCRF-CEM 20.15 59.23 103.65 116.03 77.39 7.77 49.02 58.83 48.46 
HL-60(TB) 8.41 72.97 120.12 118.34 97.61 3.67 17.11 50.76 46.34 
K-562 22.24 51.17 112.34 128.49 74.12 14.31 54.53 65.03 58.59 
MOLT-4 16.68 78.95 115.46 132.80 91.47 11.35 32.30 54.75 43.07 
RPMI-8226 24.80 41.03 127.65 133.56 80.48 9.83 37.81 74.17 62.22 
SR 38.87 51.66 108.54 103.66 70.59 11.99 53.27 60.88 45.35 
Non-Small Cell 
Lung Cancer 
A549/ATCC 35.96 20.00 76.74 138.85 32.30 2.64 12.65 43.90 28.88 
EKVX 29.59 11.57 120.17 161.32 32.49 7.32 21.69 41.82 31.03 
HOP-62 33.63 22.46 80.49 158.60 45.90 6.03 22.55 24.84 19.99 
HOP-92 0 0 78.49 109.79 4.51 3.02 11.28 40.36 28.25 
NCI-H226 48.81 33.73 51.50 26.96 35.15 5.88 13.23 24.77 21.36 
NCI-H23 69.39 68.04 134.07 132.12 90.37 2.21 21.82 44.16 39.27 
NCI-H322M 0.21 0 32.21 19.52 3.95 1.65 5.69 2.44 4.81 
NCI-H460 28.14 25.07 87.28 90.38 46.08 0 39.19 47.70 29.96 
NCI-H522 31.97 47.13 120.20 134.81 62.67 7.64 18.21 23.62 22.73 
Colon Cancer 
COLO 205 0 0 80.85 57.45 3.67 0 15.44 55.51 39.55 
HCC-2998 13.21 0 133.50 137.87 38.63 0 2.86 10.89 0 
HCT-116 39.13 44.14 132.42 150.92 109.10 8.46 63.36 72.90 59.89 
HCT-15 48.69 44.66 168.35 168.11 97.21 0 57.16 50.52 33.91 
HT29 8.23 0.35 73.95 50.97 0 5.99 26.49 69.86 50.14 
KM12 21.19 25.15 93.96 129.88 64.80 0 18.15 43.43 17.79 
SW-620 24.10 22.49 159.75 156.56 81.66 4.29 20.05 27.07 18.93 
CNS Cancer 
SF-268 32.26 41.37 91.21 110.65 54.82 15.04 19.26 37.67 29.00 
SF-295 12.21 5.24 30.80 69.03 20.44 9.26 14.92 54.00 36.89 
SF-539 7.45 12.52 198.29 194.41 94.83 0 4.73 22.07 18.69 
SNB-19 39.25 25.88 95.41 174.30 66.30 1.20 9.35 33.22 17.91 
SNB-75 63.66 66.13 194.63 198.23 110.40 20.65 27.60 46.73 41.79 
U251 17.35 29.29 99.78 181.45 67.40 8.65 42.13 46.10 26.06 
Melanoma LOX IMVI 37.84 64.25 180.28 183.86 99.49 4.55 39.20 40.06 22.40 
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MALME-3M 169.26 94.48 188.59 187.38 164.33 0 0.23 23.30 14.64 
M14 95.86 80.70 193.88 193.47 121.83 0 13.94 24.45 14.96 
MDA-MB-435 172.49 185.53 193.49 197.05 193.24 0 7.06 32.55 24.57 
SK-MEL-2 24.77 22.73 117.29 140.56 50.50 0 0.55 14.41 21.90 
SK-MEL-28 7.59 8.64 135.36 181.24 59.83 0 8.15 27.78 18.01 
SK-MEL-5 60.33 48.69 198.49 196.93 177.60 3.12 44.92 110.14 83.18 
UACC-257 37.58 47.42 172.55 190.50 128.61 0 5.58 51.31 33.52 
UACC-62 29.18 33.59 136.03 154.04 112.39 5.12 34.09 47.31 46.24 
Ovarian Cancer 
IGROV1 51.23 46.96 120.49 139.81 65.42 0 12.89 18.70 19.70 
OVCAR-3 35.24 48.92 126.39 118.83 98.89 3.35 30.37 46.79 39.78 
OVCAR-4 30.63 52.34 196.31 198.41 59.51 10.84 29.10 66.51 59.08 
OVCAR-5 0 0 165.70 177.37 0 0 0 0 0 
OVCAR-8 37.77 53.68 94.40 182.60 96.21 2.18 11.63 34.51 22.47 
NCI/ADR-RES 29.79 35.70 112.75 122.75 82.21 0.82 8.21 32.84 28.33 
SK-OV-3 23.68 27.13 44.32 38.03 40.91 4.34 19.80 17.91 21.63 
Renal Cancer 
786-0 19.04 17.33 121.83 190.37 31.40 0.60 12.69 29.94 22.26 
A498 6.32 13.32 44.03 48.42 10.55 26.71 13.08 37.26 27.25 
ACHN 57.35 57.98 195.25 190.19 74.36 0 11.65 27.66 15.91 
CAKI-1 67.87 56.64 79.67 91.15 69.16 9.75 42.98 39.11 32.21 
RXF 393 29.32 39.72 126.32 187.24 46.32 0 13.75 25.92 26.73 
SN12C 29.81 38.18 196.64 191.17 69.12 7.24 19.77 25.74 18.58 
TK-10 −8.43 0 41.72 11.39 0 0 8.81 20.32 20.52 
UO-31 66.37 61.82 135.24 173.08 78.47 32.71 42.83 57.68 49.11 
Prostate Cancer 
PC-3 33.67 42.21 99.63 102.79 69.33 14.03 54.49 62.23 51.20 
DU-145 28.33 11.20 190.66 191.42 66.79 0 7.12 25.02 12.24 
Breast Cancer 
MCF7 54.39 59.97 162.80 163.07 88.50 16.30 35.02 64.10 47.06 
MDA-MB-231/ATCC 60.00 59.61 106.76 107.49 84.61 0 10.63 7.06 4.91 
HS 578T 21.13 27.78 109.43 108.98 53.83 15.85 21.79 41.31 38.71 
BT-549 32.10 22.75 199.09 197.40 62.82 7.56 17.13 46.06 39.07 
T-47D 28.91 64.88 103.21 119.84 79.61 11.05 46.29 79.21 75.60 
MDA-MB-468 0 20.05 130.08 133.70 67.59 0 32.25 60.86 56.41 
2.2.2. In Vitro Five-Dose Full NCI 60 Cell Panel Assay 
Compounds 3c, 3d, and 3e achieved complete cell death at most cancer cell lines and were 
selected for advanced five-dose testing against the full panel of 60 human tumor cell lines. All the 
60 cell lines representing nine tumor subpanels were incubated at five different concentrations 
(0.01, 0.1, 1, 10, and 100 μM). The outcomes were used to create log concentrations versus % growth 
inhibition curves, and three response parameters (GI50, TGI, and LC50) were calculated for each cell 
line. The GI50 value (growth inhibitory activity) corresponds to the concentration of the compound 
causing a 50% decrease in net cell growth, the TGI value (cytostatic activity) is the concentration of 
the compound resulting in the total growth inhibition (TGI), and the LC50 value (cytotoxic activity) 
is the concentration of the compound causing a net 50% loss of initial cells at the end of the 
incubation period of 48 h. From the results in Table 2, it is clear that compound 3d exhibited 
remarkable anticancer activity against most of the tested cell lines, representing nine different 
subpanels. Compound 3d showed high activity against most of the tested cell lines, with the GI50 
ranging from 1.85 to 9.98 mM (Table 2). The criterion for selectivity of a compound depends upon 
the ratio obtained by dividing the full-panel MID (the average sensitivity of all cell lines toward the 
test agent) (μM) by their subpanel MID (μM). Ratios between 3 and 6 refer to moderate selectivity; 
ratios > 6 indicate high selectivity toward the corresponding cell line, while compounds not meeting 
either of these criteria rated nonselective. In this context, compound 3d was found to have broad-
spectrum antitumor activity against the nine tumor subpanels tested, with selectivity ratios ranging 
between 0.73 and 1.14 at the GI50 level. Furthermore, compound 3e exhibited remarkable anticancer 
activity against most of the tested cell lines representing nine different subpanels and showed high 
activity against most of the tested cell lines, with the GI50 ranging from 1.31 to 9.66 mM (Table 2). 
Compound 3e was found to have broad-spectrum antitumor activity against the tested nine tumor 
subpanels, with selectivity ratios ranging between 0.98 and 1.43 at the GI50 level. On the other hand, 
compound 3c revealed broad-spectrum cell growth inhibition activity against the major of the 
tested tumor subpanels, with GI50 values ranging from 1.13 to 5.77 μM and the selectivity ratio 
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ranging from 0.78 to 1.32. It can be deduced that compounds 3c, 3d, and 3e possessed broad-
spectrum antitumor agents against different tested tumor subpanels with no selectivity toward the 
tested cell lines. 
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Table 2. Results of in vitro five-doses testing of nine human cancer types and selectivity for compounds 3c, 3d, and 3e. 
Panel Cell Line 





































>100 >100 9.98 
7.87 0.73 
3.33 >3.33 2.53 
2.14 1.16 
>100 >100 
HL-60(TB) 3.95 3.26 >100 7.70 2.05 >3.33 2.18 6.26 >100 
K-562 1.69 -- >100 8.79 3.33 >3.33 2.43 >100 >100 
MOLT-4 1.22 5.76 >100 5.99 1.72 >3.33 2.22 8.89 >100 
RPMI-8226 2.21 -- >100 7.17 2.01 >3.33 1.86 6.47 >100 






5.61 >100 8.35 
5.07 1.14 
2.07 >3.33 2.42 
2.31 1.07 
6.07 >100 
EKVX 1.39 3.46 8.60 5.01 1.15 2.64 1.87 1.25  
HOP-62 1.96 4.85 1.65 1.85 6.48 1.53 4.28 1.72  
HOP-92 1.56 4.19 >100 7.41 2.60 1.56 2.26 1.44  
NCI-H226 1.61 3.35 6.99 9.36 4.09 1.37 1.81 5.83  
NCI-H23 1.46 3.76 9.72 5.50 1.50 >3.33 1.31 4.32 >100 
NCI-H322M 1.55 2.92 5.50 1.61 5.90 1.43 1.93 5.13  
NCI-H460 1.94 3.97 8.11 1.06 3.60 1.50 3.35 1.22  
NCI-H522 1.49 4.19 >100 5.51 1.37 4.64 1.60 4.69 >100 
Colon 
Cancer 
COLO 205 1.94 
2.61 0.84 
4.24 9.28 3.63 
5.99 0.96 
9.06 2.26 3.36 
2.50 0.99 
1.27 6.62 
HCC-2998 1.62 3.14 6.06 9.48 2.91 1.06 2.34 6.67 2.40 
HCT-116 5.77 2.58 9.31 6.67 1.70 6.89 1.94 6.45 2.73 
HCT-15 1.52 3.50 8.07 5.49 1.18 2.54 1.51 3.24 6.96 
HT29 3.09 >100 >100 1.15 3.18 >3.33 3.32 2.87 >100 
KM12 2.68 8.80 9.05 9.99 3.56 >3.33 3.12 1.37 8.18 




4.48 >100 6.15 
5.12 1.13 
1.65 >3.33 2.54 
2.43 1.02 
1.10 5.91 
SF-295 1.68 3.08 5.66 6.15 1.27 2.60 3.55 1.27 3.57 
SF-539 1.69 3.12 5.79 5.54 1.02 1.89 1.67 3.06 5.58 
SNB-19 1.67 3.44 7.05 6.45 1.64 5.31 3.09 1.17 3.42 
SNB-75 8.43 2.76 7.79 1.32 7.46 1.74 1.32 6.04 2.51 
U251 1.60 4.28 >100 5.12 1.12 2.43 2.41 1.11 >100 
Melanoma 
LOX IMVI 5.32 
2.32 0.95 
2.10 5.86 4.06 
5.77 1.00 
9.04 2.01 9.66 
3.12 0.79 
2.62 6.98 
MALME-3M 3.83 1.58 4.00 4.42 8.70 1.71 5.70 1.75 4.19 
M14 1.63 3.30 6.65 5.54 1.06 2.01 1.33 2.83 6.03 
MDA-MB-
435 
1.94 3.63 6.82 5.98 1.09 1.97 1.76 3.23 5.93 
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SK-MEL-2 1.74 4.32 7.27 7.39 1.58 9.60 2.47 7.25 9.29 
SK-MEL-28 1.87 3.35 6.00 6.87 1.21 2.15 2.40 5.22 1.39 
SK-MEL-5 1.41 2.75 5.37 5.51 1.02 1.89 1.43 2.76 5.32 
UACC-257 1.55 3.15 6.39 5.93 1.14 2.20 1.69 3.41 6.88 





3.21 9.08 4.46 
5.38 1.07 
1.31 5.78 1.16 
2.53 0.98 
4.74 2.58 
OVCAR-3 3.28 1.43 5.03 5.22 1.28 3.16 1.53 4.42 1.59 
OVCAR-4 1.26 2.56 5.18 4.54 8.87 1.73 1.61 4.58 1.59 
OVCAR-5 2.03 4.37 9.42 5.86 1.15 2.26 1.83 3.53 6.79 
OVCAR-8 2.13 1.12 >100 5.81 1.24 2.63 2.62 1.16 4.10 
NCI/ADR-
RES 
2.24 -- >100 7.43 2.17 >3.33 1.93 6.77 >100 





5.70 >100 7.48 
4.82 1.20 
1.70 >3.33 2.75 
2.53 0.98 
7.93 9.61 
A498 1.05 4.70 >100 6.93 2.90 >3.33 2.07 6.34 >100 
ACHN 1.42 2.91 5.96 4.92 9.65 1.89 1.39 3.03 6.60 
CAKI-1 1.18 2.86 6.92 4.80 2.14 8.98 2.48 1.49 3.87 
RXF393 1.35 2.71 5.43 5.02 9.86 1.94 1.85 4.75 1.50 
SN12C 1.22 2.79 6.42 5.06 1.07 2.24 1.33 2.61 5.11 
TK-10 4.48 8.14 4.13 1.03 1.71 2.85 1.84 3.47 6.54 





8.81 >100 6.20 
6.29 0.92 
2.69 >3.33 1.62 
1.74 1.43 
1.07 >100 





3.36 9.17 5.83 
6.67 0.87 





1.27 6.69 >100 6.52 2.69 >3.33 1.37 9.82 >100 
HS 578T 2.04 6.93 >100 7.82 2.05 >3.33 2.09 6.03 >100 
BT-549 1.53 2.91 5.54 5.22 9.83 1.85 1.50 2.91 5.64 
T-47D 2.03 7.29 >100 6.98 2.30 >3.33 2.49 1.44 >100 
MDA-MB-
468 
2.28 5.72 >100 7.66 2.04 >3.33 2.55 7.32 >100 
MID a 2.20 5.77 2.48 
MID a = Average sensitivity of all cell lines in mM and MID b = average sensitivity of all cell lines of a particular subpanel in μM. 
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2.2.3. Evaluation of In Vitro Antiproliferative Activities against Melanoma SK-MEL-5 Cancer Cell 
Line and Nontumorigenic SK-MEL-5 Cell Line 
The synthesized compounds 3b, 3c, 3e, and 8a–d, as well as Dinaciclib (the reference 
compound), were evaluated for their antiproliferative activity by being treated at a concentration of 
50 μM (Table 3). The antiproliferative assay was performed with melanoma SK-MEL-5 cells, 
whereas most of our goal compounds exhibited the highest potency; the assay was done for four 
days and, then, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
GraphPad Prism software (GraphPad Software, San Diego, CA, USA) was used to calculate the 
median inhibition concentration (IC50) for the tested compounds (Figure 5). The difference in the 
results was considered significant when the values of p were less than 0.05. 
Table 3. Antiproliferative activity of the target compounds 3b, 3c, 3e, 8a–d, 9, Dinaciclib, and the control. 
Compound Cytotoxicity IC50 (µM) a ± SEM 
3b 9.11 ± 0.39 *** 
3c 0.81 ± 0.03 *** 
3e 4.18 ± 0.18 *** 
8a 26.5 ± 1.13 ** 
8b 21.5 ± 0.92 ** 
8c 30.8 ± 1.32 ** 
8d 87.3 ± 3.73 * 
9 12.1 ± 0.52 *** 
Dinaciclib 5.97 ± 0.25 *** 
Control 0 
a IC50 = compound concentration required to inhibit tumor cell proliferation by 50%. All data were 
obtained by triplet testing data are expressed as the mean ± SEM from the dose-response curves of 
at lowest three independent experiments. Results were significantly different from the control at *** 
p < 0.05. Results indicating at *, ** means less significant.  
As shown in Table 3, the most active three paracyclophane/thiazole conjugates bearing the 
naphthoquinone moiety, 3b, 3c, and 3e, exhibited potent-to-remarkable proliferation inhibition of 
cancer cells, with IC50 of 9.11, 0.81, and 4.18 μM compared to Dinaciclib with an IC50 of 5.97 μM. On 
the other hand, all other compounds bearing the naphthyl moiety instead showed moderate activity 
against the growth of the cancer cell line. From these results, we can conclude that the presence of 
the naphthoquinone moiety improve binding with the target protein, in addition to substitution 
with the benzyl, allyl, or cyclopropyl groups, which would enhance the antiproliferative activity, 
especially upon increasing the flexibility of the compounds (as in compounds 3c and 3e); this 
extension increased the antiproliferation potency of these compounds against melanoma SK-MEL-5. 
It is interesting to mention that the proliferation inhibitory results were positively correlated with 
the anticancer results obtained from the NCI on the tested cancer cell lines. 
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Figure 5. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of 3b, 3c, 3e, 
8a–d, 9, and Dinaciclib on the melanoma SK-MEL-5 cell line relative to the control. IC50: inhibitory 
concentration (50%). Results indicating at *, **, *** means less significant 
According to the screening results, and to better explore the structure-activity relationship 
(SAR) of the compounds, besides the biochemical assay (IC50) on the SK-MEL-5 cancer cell line, we 
also evaluated the compound’s cellular antiproliferative activity, using the WI38 cell line normal 
lung cells of a three-month-gestation aborted female fetus to monitor the general cytotoxicity as 
well (Table 4). Independently, compounds 3c and 3e showed the lowest IC50 values among the 
tested compounds against the SK-MEL-5 leukemia cancer cells; therefore, we were encouraged to 
select 3c and 3e for further investigation for its antiproliferation on normal, healthy, unaffected cell 
lines by MTT assay (Table 4). 
Compounds 3c and 3e achieved IC50 values of 32.59 and 39.86 μM, respectively, on the selected 
normal WI38 cell line, which is greater than of the reference Dinaciclib IC50 = 22.01 μM. The gained 
results indicated the relative safety of the tested compounds on normal cells; they also showed a 
good selectivity window between normal cells and cancer cells. 
Table 4. Antiproliferative IC50 ± SEM (μM) activity of compounds 3c, 3e, and Dinaciclib. 
Compound 
Cytotoxicity IC50 ± SEM (µM)  
WI38 
  32.59 ± 1.44 
3e 39.86 ± 1.76 
Dinaciclib 22.01 ± 0.97 
The data given are mean values derived from at lowest three replicates ± SEM. 
Structure-Activity Relationship 
Based on the previous results, we can deduce that when the [2.2]paracyclophane/thiazole 
conjugated with the naphthoquinone moiety, as in series I, it exhibited better antitumor activity 
than their naphthyl-containing congeners (series II and series III). This could be attributed to the 
specific interaction with the proposed CDKK1 enzyme that is absent in series II and III, hence, 
revealed weak activity. Meanwhile, the antiproliferation toward the melanoma SK-MEL-5 cell line 
concerning series I showed the highest potency upon substitution of R on thiazole imine with small 
molecules such as allyl, ethyl, and cyclopropyl; however, when R was replaced with phenyl and 
benzyl, the activity was particularly attenuated, which may be probably due to their steric 
hindrance effects. Since the target compounds 3a–e revealed interesting antitumor activity, this 
work underwent further enzymatic mechanistic investigations to prove exactly the explained 
hypothesis. 
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2.3. Selectivity Profiling of Compound 3c 
Given the fact that 3c exhibited the best in vitro biochemical activity against SK-MEL-5, the 
antiproliferative efficacy in cancer cell lines, and to investigate whether the antiproliferative 
activities of 3c was related to the interaction with CDK may play critical roles in the regulation of 
the cell cycle or/and transcription. We chose this compound for further selectivity evaluations 
toward different kinases. We first subjected 3c to examine the selectivity among eight different CDK 
isoforms that are available (CDK1, 2, 3, 4, 5, 6, 7, and 9) in comparison to the reference Dinaciclib 
using a Kinase-Glo® MAX kit and incubated the tested compounds at 30 °C for 45 min [36] (Figure 
6). 
Interestingly, 3c potently inhibited the CDK kinase, showing IC50 in nanomolar values. 
Moreover, it exhibited the selectivity toward CDK1, 2, and 9 with an IC50 of 54.8, 59.8, and 61.6 nM 
in comparison to Dinaciclib with an IC50 of 21.3, 15.3, and 20.6 nM, indicating a more than 10-fold 
selectivity over CDK3, 4, 5, 6, 7. It is noteworthy that compound 3c revealed the best selectivity 





IC50(nM) ± SEM 
3c Dinaciclib 
CDK1 54.8 21.3 
CDK2 59.8 15.3 
CDK3 71.4 139 
CDK4 191 109 
CDK5 283 42.6 
CDK6 422 139 
CDK7 526 137 
CDK9 61.6 20.6 
 
Figure 6. Selectivity profiling of compound 3c and Dinaciclib. (A,B) Biochemical testing of 3c against 
CDK isoforms on the SK-MEL-5 cell line. All data were obtained by triplet testing. 
2.4. Inhibition of Phospho-CDK1/CDC2 Cell-Based Phosphorylation in SK-MEL-5 Cancer Cells 
As it is understood by those skilled in the drug discovery art, kinase inhibitors should possess 
both high affinities for the target kinase, as well as high selectivity versus other protein kinases. 
Therefore, we next investigated the cellular mode of action of the most potent tested inhibitor 3c 
using an anti-CDC2 (phospho-Tyr15) antibody via the Enzyme-Linked Immunosorbent Assay 
(ELISA) assay method to show the capability of 3c to downregulate the CDK1-phosphorylated 
substrate and the loss of cyclin expression in treated cells. The anti-CDC2 (phospho-Tyr15) 
antibody is a rabbit polyclonal antibody. The treatment of SK-MEL-5 cells with 3c for a period of 24 
h showed a reduction of phosphorylation at Tyr15. 
Figure 7 illustrates that compound 3c revealed a significant downregulation of phospho-Tyr15 
with a level of 7.45 pg/mL, which is close to the reference inhibitor (6.42 pg/mL) in comparison to 
the control group (32.04 pg/mL). Compound 3c caused a CDK1 phospho-Tyr15 down-expression 
level about 76.74-fold change comparable to the reference (80.02-fold change) relative to the control 
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Figure 7. Effect of 3c and Dinaciclib on CDK1/CDC2 phospho-Tyr15 regulation in the SK-MEL-5 cell 
line. (A) Enzyme-Linked Immunosorbent Assay (ELISA) for the immunogen phosphor-peptide for 
3a and Dinaciclib and nonphosphopeptide for the control group using the anti-CDC2 (phospho-
Tyr15) antibody. (B) CDK1/CDC2 phospho-Tyr15 inhibition (conc. (pg/mL) ± SEM) of compound 3c 
and Dinaciclib. All data were obtained by triplet testing. Results were significantly different from 
the control at *** p < 0.05. 
2.5. Cell Cycle Analysis 
The cell cycle analysis was carried out for the most potent compound 3c against the SK-MEL-5 
melanoma cancer cell line. The assay was carried out using cytometers, which are Becton Dickinson 
Immuno-Cytometry Systems, Beckman/Coulter Inc., DACO/cytomation, and PARTEC GmbH, Brea, 
CA 94043 USA. The results of the annexin V/PI flow cytometry of SK-MEL-5 cells were repeated 
three times after treatment with an IC50 value (0.81 μM) of 3c. The results showed that the 
percentage of cells of SK-MEL-5 in the G0/G1 phase of the cell cycle in the control was 56.29%, 
which is remarkable to a Dinaciclib of 41.43%, and recorded a remarked decrease to 37.26% upon 
treatment with 3c (see Table S1, Supplementary Data). The G2/M phase exhibited a noteworthy 
percent increase that reached 36.36% because of the cell accumulation at this phase. Moreover, the 
apoptotic cell percentage for the phase pre-G1 was raised from 1.61% for the untreated control to 
36.41% and 32.84% in comparison to treated cells with compound 3c and Dinaciclib, respectively, 
(upper right quadrant of the cytogram) (Figure 8). The gained results indicated that the late-
apoptosis percent was greater than that of early apoptosis, which was considered a good sign for 
irreversible apoptosis (Figures 9 and 10). According to the above results, it is clear that compound 
3c exhibited pre-G1 apoptosis and cell cycle arrest at the G2/M phase. Therefore, the results 
revealed that the tested compound was not cytotoxic but antiproliferative, causing programmed 






























Conc. (pg/mL) Fold change 
3c 7.45 ± 0.4 *** 76.74157 
Dinaciclib 6.42 ± 0.07 *** 80.01873 
control 32.04 ± 3.1 0 
 








Figure 8. Cell cycle analysis and apoptosis induction analysis against SK-MEL-5 using annexin V/PI at 
IC50. Concentrations representing the growth arrest at the pre-G1 (G0) and G2/M phases. (A) Untreated 
cells, (B) treated cells with Dinaciclib, and (C) treated cells with 3c. The test was repeated three times, and 
3c and the reference were incubated for 24 h (2 × 105 cells/well) at 37 °C. 
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Figure 10. Cell cycle analysis on the SK-MEL-5 melanoma cell line treated with the compound. 
2.6. Caspase-3 Activation Assay 
The intracellular caspase-3 signaling was studied using the ELISA analysis method and 
replicated three times to understand the molecular mechanisms by which 3c induces G2/M phase 
arrest. Caspase-3 is essential for the apoptotic signal spreading after exposure to the antimitotic 
compounds [37], the effect of paracyclophane/thiazole conjugate 3c on the caspase-3 activated 
enzyme. Compound 3c was evaluated against the SK-MEL melanoma cancer cell line at 
concentrations of 2500, 1250, 625, 313, 156, 78, and 39 pg/mL. Table 5 displays the results that 
revealed that compound 3c possessed a remarkable overexpression of the caspase-3 protein level 
(519.4 pg/mL), which is compared to the reference Dinaciclib (476.7 pg/mL). Compound 3c caused 
overexpression of the caspase-3 protein level about 8.66-fold change higher than the reference (7.95-
fold change) relative to the control (Figure 11). Hence, it could be deduced from the above results 
that apoptosis may be attributed to the overexpression of caspase-3, which was induced by the 
tested compounds. 
Table 5. Caspase-3 conc. (pg/mL) ± SEM and fold change levels for 3c and Dinaciclib on the SK-
MEL-5 cell line. 
Compound 
Caspase 3 
Conc. pg/mL Fold Change 
3c 519.4 ± 5.8 *** 8.66 
Dinaciclib 476.7 ± 8.4 *** 7.95 
Control 59.95 ± 2.1 1 
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Figure 11. Caspase-3 levels of 3c and Dinaciclib on the SK-MEL-5 line relative to the control. Results 
indicating at *** means less significant. 
2.7. Molecular Modeling 
Before docking calculations, validation of the employed Autodck4.2.6 parameters and protocol 
were first performed based on the available experimental data. The co-crystallized Dinaciclib in the 
complex with CDK1 (PDB code: 6GU6) was redocked, and the binding mode was predicted and 
compared to the experimental structure (Figure 12). 
 
Figure 12. (a) 3D representation of the predicted binding mode (in grey) and experimental structure 
(in cyan) of Dinaciclib, (b) 2D and 3D representations of the binding pose and ligand interactions of 
3c, and (c) 2D and 3D representations of the binding pose and ligand interactions of 8c with the 
CDK1 receptor (PDB: 6GU6). 
A comparison of the predicted docked structure with the corresponding resolved crystal 
structure revealed that the Autodock4.2.6 with the employed parameters accurately predicted the 
correct binding mode of Dinaciclib inside the active site of CDK1, forming two essential hydrogen 
bonds with LYS38 and LEU88 (Figure 12). The estimated root mean square deviation (RMSD) 
between the experimental and docked structures was 0.2 Å. 
Utilizing the molecular docking, the binding modes and affinities of the synthesized 
compounds 3a–e, 8a–d, and 9 with the CDK1 active site were then investigated. The calculated 
docking scores for the synthesized compounds are listed in Table S2. As can be seen from Table S2, 
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all synthesized compounds gave good binding affinities towards CDK1, with values in the range 
−8.6 to −9.5 kcal/mol, relative to that of Dinaciclib (−10.6 kcal/mol), supporting that CDK1 inhibition 
is a plausible mechanism explaining the antitumor activity observed with those compounds. 
Compared to compounds 8a–d, there were better binding affinities with CDK1 for compounds 3a–e 
containing the naphthoquinone scaffold, showing the specific interaction of the oxygen atom with 
the amino acid residue GLN137 (Figure 12). This suggests the moderately higher antitumor activity 
than the other derivatives 8a–d and 9 lacking the naphthoquinone scaffold. 
Among the paracyclophane/thiazoles-naphthoquinones conjugates 3a–e, compound 3c showed 
the highest binding affinity, with a docking score of −9.5 kcal/mol, forming four hydrogen bonds 
with GLN137 (1.88, 2.65, and 2.95 Å) and ILE15 (2.78 Å) (Figure 12). Besides, pi-based and 
hydrophobic interactions between 3c and the key amino acid residues inside the active site were 
also observed (Figure 12). 
The contribution of the paracyclophane moiety to inhibit CDK1 is questionable. To address the 
answer, p-xylene analogs of compounds 3a–e were modeled, and their binding scores with CDK1 
were predicted (Table S3). According to the data listed in Table S3, the p-xylene analogs showed 
relatively lower docking scores, with values in the range of −8.1 to −8.7 kcal/mol, compared to 
paracyclophane-based 3a–e (docking scores of −9.3 to −9.8 kcal/mol), confirming the favorable 
contribution of the paracyclophane moiety in pi-based interactions with the CDK1 active site. 
3. Experimental 
3.1. Chemistry 
The IR spectra were recorded by the ATR technique (ATR = attenuated total reflection) with an 
FT device (FTIR Bruker IFS 88, Middlesex County, MA, USA), Institute of Organic Chemistry, 
Karlsruhe Institute of Technology, Karlsruhe, Germany. The NMR spectra were measured in 
DMSO-d6, chloroform-d, and acetone-d6 on a Bruker AV-400 spectrometer 400 MHz for 1H and 100 
MHz for 13C, and the chemical shifts were expressed in δ (ppm) versus internal tetramethylsilane 
(TMS) = 0 for 1H and 13C and external liquid ammonia = 0 at in the Chemistry Department, Florida 
Institute of Technology, 150WUniversity Blvd, Melbourne, FL 32901, USA. The description of the 
signals includes: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
doublet, and ddd = doublet of dd. Mass spectra were recorded on a FAB (fast atom bombardment) 
Thermo Finnigan Mat 95 (70 eV) and ESI (electrospray ionization-mass spectrometry, Florida 
Institute of Technology, 150WUniversity Blvd, Melbourne, FL 32901, USA) Thermo-Fisher 
QExactive Plus. For the high-resolution mass (HRMS), the following abbreviations were used: calc. 
= theoretically calculated mass and found = mass found in the analysis, Institute of Organic 
Chemistry, Karlsruhe University, Karlsruhe, Germany. TLC was performed on analytical Merck 
9385 silica aluminum sheets (Kieselgel 60)Aldrich, USA with a Pf254 indicator; TLC were viewed at 
λmax = 254 nm. Crude products were purified by flash chromatography with Silica gel 60 (0.040 × 
0.063 mm; Geduran®) (Merck, Kenilworth, NJ, USA). 
3.1.1. Starting Materials 
N-Substituted [2.2]paracyclophenylhydrazinecarbothioamides 1a-e were prepared according 
to the literature [40], whereas compounds 2 and 4 were bought from Aldrich (St. Louis, MO, USA). 
3.1.2. Reactions of Hydrazinecarbothioamides 1a–e with DCHNQ (2); Preparation of Compounds 
3a–e 
2,3-Dichloro-1,4-naphthoquinone 0.250 g (2, 1.1 mmol, 1.10 equiv.) was added to a stirred 
solution of 1a–e (1.0 mmol, 1.00 equiv.) in 25 mL dry CH3CN. The resulting solution was stirred at 
room temperature for 16 h. After S-alkylation was completed, and the dried salt was dissolved in 
dry CH3CN; after which, triethylamine (1.1 mmol) and triphenylphosphine (1.1 mmol) were added. 
The resulting mixture was left under reflux for about 8-10 h. The reaction mixture was then left to 
cool at room temperature; then, H2O (50 cm3) was added. The resulting solution was extracted with 
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CH2Cl2. The organic extracts were dried over anhydrous CaCl2, filtered, and evaporated under 
reduced pressure. The crude was purified by flash chromatography by using cyclohexane/ethyl 
acetate (10:4) as the eluent to afford 3a–e. 
3.1.3. (Z)-N-(4,9-Dioxo-2-(phenylimino)-4,9-dihydronaphtho[2,3-d]thiazol-3(2H)-yl)-4′-
[2.2]paracyclophanylamide (3a) 
Red crystal (methanol), yield: 0.390 g (70%). 1H NMR (400 MHz, acetone-d6, ppm) δ = 10.41 (s, 
1H, amide-NH), 8.20–8.09 (m, 2H, Ar-H), 7-92–7-87 (m, 2H, Ar-H), 7.48–7.42 (m, 1H, Ph-H), 7.23–
7.05 (m, 4H, Ph-H), 6.85–6.77 (m, 2H, PC-H), 6.70–6.56 (m, 5H, PC-H), 3.87–3.79 (m, 1H, PC-CH2), 
3.27–3.20 (m, 1H, PC-CH2), 3.14–3.05 (m, 3H, PC-CH2), 2.98–2.85 (m, 3H, PC-CH2). 13C NMR (100 
MHz, acetone-d6, ppm) δ = 177.4, 174.2 (naphthoquinone-CO), 167.9 (amide-CO), 154.3 (thiazole-
C2), 150.5 (Ph-C), 142.1 (PC-C-6′), 141.8 (PC-C-11′), 141.1 (PC-C-14′), 140.9 (PC-C-3′), 140.7, 140.2 
(Ar-C), 140.1 (PC-CH), 137.2 (Ar-C), 136.9, 135.2, 134.9, 133.9 (Ar-CH), 133.7 (PC-C-4′), 133.6, 133.3, 
133.1, 132.9 (PC-CH), 132.8, 132.7, 130.7 (Ph-CH), 127.7, 126.7 (PC-CH), 125.4, 121.5 (Ph-CH), 108.3 
(Ar-C), 35.8 (PC-CH2-1′), 35.6 (PC-CH2-10′), 35.5 (PC-CH2-9′), 35.3 (PC-CH2-2′). IR (ATR, cm−1) ṽ = 
3325–3165 (w, NH), 2925 (s, Ar-CH), 2847 (s, aliph-CH) 1669, 1632, 1587 (CO), 1567 (C=N). MS 




Red crystal (methanol), yield: 0.370 g (65%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 11.26 (s, 
1H, amide-NH), 8.10–8.01 (m, 2H, Ar-H), 7.90–7.84 (m, 2H, Ar-H), 748–7.02 (m, 5H, Ph-H), 6.78–6.37 
(m, 7H, PC-H), 4.12 (s, 2H, CH2Ph), 3.26–2.67 (m, 8H, PC-CH2). 13C NMR (100 MHz, DMSO-d6, ppm) 
δ = 178.8, 176.2 (naphthoquinone-CO), 174.7 (amide-CO), 173.0 (thiazole-C2), 140.5 (Ph-C), 139.5 
(PC-C-6′), 139.0 (PC-C-11′), 138.9 (PC-C-14′), 138.2 (PC-C-3′), 135.7, 135.6 (Ar-C), 134.6 (Ar-C), 134.5, 
134.2, 132.7, 132.5 (Ar-CH), 132.4 (PC-C-4′), 132.0, 131.6, 131.5, 131.4, 131.3 (PC-CH), 128.2, 128.1, 
127.8, 127.3, 127.2 (Ph-CH), 127.0, 126.6 (PC-CH), 126.1 (Ar-C), 57.3 (CH2Ph), 34.8 (PC-CH2-1′), 34.6 
(PC-CH2-10′), 34.5 (PC-CH2-9′), 34.4 (PC-CH2-2′). IR (ATR, cm−1) ṽ = 3407–3288 (w, NH), 2917 (s, Ar-
CH), 2851 (s, aliph-CH) 1681, 1649, 1585 (CO), 1511 (C=N). MS (FAB) m/z (%) = 570.3 [M + H]+ (65). 
HRMS (FAB; [M + H]+, C35H28O3N332S1) Calc.: 570.1851, Found: 570.1854. 
3.1.5. (Z)-N-(2-(Allylimino)-4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-3(2H)-yl)-4′-
[2.2]paracyclophanylamide (3c) 
Red crystal (methanol), yield: 0.350 g (67%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 11.28 (s, 
1H, amide-NH), 8.42–7.76 (m, 4H, Ar-H), 7.03–6.70 (m, 2H, PC-H), 6.64–6.35 (m, 5H, PC-H), 6.06–
5.65 (m, 1H, allyl-CH=), 5.43–4.97 (m, 2H, allyl-CH2), 4.05–3.78 (m, 2H, allyl-CH2=), 3.65–3.54 (m, 1H, 
PC-CH2), 3.18–2.73 (m, 7H, PC-CH2). 13C NMR (100 MHz, DMSO-d6, ppm) δ = 178.6, 176.0 
(naphthoquinone-CO), 174.6 (amide-CO), 166.6 (thiazole-C2), 139.4 (PC-C-6′), 139.3 (PC-C-11′), 
139.1 (PC-C-14′), 138.8 (PC-C-3′), 135.6, 135.4 (Ar-C), 134.4, 134.2, 134.0, 133.6 (PC-CH), 132.5 (Ar-
2CH), 132.3 (Ar-C), 131.8 (allyl-CH=), 131.3 (PC-C-4′), 131.2, 131.1, 126.7 (PC-CH), 126.5, 126.0 (Ar-
CH), 116.4 (allyl-CH2=), 115.3 (Ar-C), 45.8 (allyl-CH2), 34.6 (PC-CH2-1′), 34.5 (PC-CH2-10′), 34.4 (PC-
CH2-9′), 34.3 (PC-CH2-2′). IR (ATR, cm−1) ṽ = 3425–3165 (w, NH), 2921 (s, Ar-CH), 2847 (m, aliph-
CH) 1672, 1650, 1589 (CO), 1564 (C=N). MS (FAB) m/z (%) = 520.2 [M + H]+ (60). HRMS (FAB; [M + 
H]+, C31H26O3N332S1) Calc.: 520.1695, Found: 520.1693. 
3.1.6. (Z)-N-(2-(Ethylimino)-4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-3(2H)-yl)4′-
[2.2]paracyclophanylamide (3d) 
Red crystal (methanol), yield: 0.290 g (57%). 1H NMR (400 MHz, acetone-d6, ppm) δ = 10.17 (s, 
1H, amide-NH), 8.10–7.84 (m, 4H, Ar-H), 7.16–6.85 (m, 1H, PC-H), 6.74–6.54 (m, 4H, PC-H), 6.52–
6.39 (m, 2H, PC-H), 3.21–2.87 (m, 8H, PC-CH2), 1.58–1.16 (m, 2H, ethyl-CH2), 0.99 (t, J = 7.2 Hz, 3H, 
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ethyl-CH3). 13C NMR (100 MHz, acetone-d6, ppm) δ = 179.9, 177.3 (naphthoquinone-CO), 175.9 
(amide-CO), 141.1 (thiazole-C2), 140.9 (PC-C-6′), 140.8 (PC-C-11′), 140.2 (PC-C-14′), 140.1 (PC-C-3′), 
136.6 (PC-CH), 135.4 (Ar-2C), 135.0, 134.8, 133.9 (PC-CH), 133.8 (Ar-2CH), 133.2 (Ar-C), 133.1, 132.9, 
132.8 (PC-CH), 128.0 (PC-C-4′), 127.6, 127.2 (Ar-CH), 126.7 (Ar-C), 50.1 (ethyl-CH2), 36.0 (PC-CH2-
1′), 35.9 (PC-CH2-10′), 35.8 (PC-CH2-9′), 35.7 (PC-CH2-2′), 14.2 (ethyl-CH3). IR (ATR, cm−1) ṽ = 3435–
3150 (w, NH), 2925 (s, Ar-CH), 2847 (m, aliph-CH) 1667, 1647, 1589 (CO), 1562 (C=N). MS (FAB) m/z 
(%) = 508.2 [M + H]+ (50). HRMS (FAB; [M + H]+, C30H26O3N332S1) Calc.: 508.1695, Found: 508.1693. 
3.1.7. (Z)-N-(2-(Cyclopropylimino)-4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-3(2H)-yl)-4′-
[2.2]paracyclophanylamide (3e) 
Red crystal (methanol), yield: 0.285 g (55%). 1H NMR (400 MHz, CDCl3-d, ppm) δ = 10.12 (s, 
1H, amide-NH), 8.13–8.05 (m, 2H, Ar-H), 7.76–7.69 (m, 2H, Ar-H), 7.12–6.91 (m, 1H, PC-H), 6.76–
6.43 (m, 6H, PC-H), 3.22–2.96 (m, 8H, PC-CH2), 2.58–2.54 (m, 1H, cyclopropyl-CH), 1.72–1.74 ppm 
(m, 1H, cyclopropyl-CH2), 1.20-0.47 (m, 3H, cyclopropyl-CH2). 13C NMR (100 MHz, CDCl3-d, ppm) δ 
= 179.5, 176.8 (naphthoquinone-CO), 173.6 (amide-CO), 167.8 (thiazole-C2), 141.1 (PC-C-6′), 140.3 
(PC-C-11′), 139.3 (PC-C-14′), 136.4 (PC-C-3′), 135.8, 134.9 (Ar-C), 134.4 (PC-CH), 134.2 (Ar-C), 133.9, 
133.8, 133.2, 132.7 (Ar-CH), 132.3 (PC-C-4′), 132.0, 131.6, 127.7, 127.3, 127.1, 126.6 (PC-CH), 126.3 
(Ar-C), 35.6 (PC-CH2-1′), 35.4 (PC-CH2-10′), 35.2 (PC-CH2-9′), 34.9 (PC-CH2-2′), 26.0 (cyclopropyl-
CH), 7.9 (cyclopropyl-CH2), 7.5 (cyclopropyl-CH2). IR (ATR, cm−1) ṽ = 3306 (w, NH), 2925 (s, Ar-
CH), 2856 (m, aliph-CH) 1672, 1664, 1587 (CO), 1561 (C=N). MS (FAB) m/z (%) = 520.2 [M + H]+ (60). 
HRMS (FAB; [M + H]+, C31H26O3N332S1) Calc.: 520.1695, Found: 520.1693. 
3.1.8. Reactions of Hydrazinecarbothioamide Derivatives 1a–f with 2-bromo-2′-acetonaphthone (4); 
Preparation of Compounds 8a–d and 9. 
A solution of 1a–e (1.0 mmol, 1.00 equiv.) dissolved in 50 mL EtOAc was added to a solution of 
4 (0.0249 g, 1.0 mmol, 1.00 equiv.) dissolved in 20-mL ethyl acetate. The resulting solution was 
stirred at room temperature for about 24–48 h (the reaction was monitored by thin-layer 
chromatography). The formed precipitate was filtered and washed with ethyl acetate several times 
(3 × 20 mL) to afford the target product. After removal of the solvent under reduced pressure, the 
crude was purified by flash chromatography using cyclohexane/ethyl acetate (10:8) as the eluent to 
afford compounds 8a–d and 9. 
3.1.9. 2-(2-(4′-[2.2]Paracyclophonyl)hydrazinyl)-4-(naphth-2-yl)-3-phenylthiazol-3-ium Bromide (8a) 
Colorless crystal (ethanol), yield: 0.5 g (79%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 12.05 (s, 
1H, amide-NH), 8.55 (s, 1H, Ar-H), 8.27–8.12 (m, 3H, Ar-H), 7.91–7.85 (m, 1H, Ar-H), 7.76–7.69 (m, 
2H, Ar-H), 7.64–7.53 (m, 5H, Ph-H), 7.52 (s, 1H, thiazole-CH), 7.45 (s, 1H, NH), 6.64–6.57 (m, 1H, 
PC-H), 6.51–6.27 (m, 6H, PC-H), 3.53–3.42 (m, 1H, PC-CH2), 3.11–2.64 (m, 7H, PC-CH2). 13C NMR 
(100 MHz, DMSO-d6, ppm) δ = 165.6 (amide-CO), 142.0 (thiazole-C2), 141.4 (thiazole-C4), 139.3 (Ph-
C), 139.0 (PC-C-6′), 138.4 (PC-C-11′), 138.3 (PC-C-14′), 138.2 (PC-C-3′), 136.5, 135.8 (Ar-C), 133.6, 
132.7, 132.4 (PC-CH), 132.3 (Ar-C), 132.2, 131.5, 131.3 (Ar-CH), 130.4 (Ar-2CH), 130.3, 129.9 (Ar-CH), 
129.4 (PC-C-4′), 128.6 128.5, 129.6, 128.9 (PC-CH), 128.3, 127.9, 127.3, 126.4, 124.5 (Ph-CH), 123.5 
(thiazole-CH), 34.4 (PC-CH2-1′), 34.2 (PC-CH2-10′), 34.1 (PC-CH2-9′), 34.0 (PC-CH2-2′). IR (ATR, 
cm−1) ṽ = 3264–3058 (w, NH), 2925 (w, Ar-CH), 2857 (w, aliph-CH) 1694 (s, CO), 1560 (s, C=N). MS 
(ESI) m/z (%) = 552.2 [M]+ (100). HRMS (ESI, [M]+, [C36H30ON332S1]+) Calc.: 552.2104, Found: 552.2085. 
3.1.10. 2-(2-(4′-[2.2]Paracyclophonyl)hydrazineyl)-3-benzyl-4-(naphth-2-yl)-thiazol-3-ium Bromide 
(8b) 
Colorless crystal (ethanol), yield: 0.460 g (71%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 11.04 
(s, 1H, amide-NH), 8.03–7.89 (m, 4H, Ar-H), 7.65–7.50 (m, 3H, Ar-H), 7.34–7.28 (m, 3H, Ph-H), 7.21 
(s, 1H, thiazole-CH), 7.06 (d, J = 8.2 Hz, 2H, Ph-H), 6.92 (s, 1H, NH), 6.74 (dd, J = 7.8, 1.8 Hz, 1H, PC-
H), 6.70–6.53 (m, 6H, PC-H), 5.38 (s, 2H, CH2Ph), 3.75–3.69 (m, 1H, PC-CH2), 3.21–2.93 (m, 7H, PC-
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CH2). 13C NMR (100 MHz, DMSO-d6, ppm) δ = 172.8 (amide-CO), 166.8 (thiazole-C2), 142.2 
(thiazole-C4), 140.4 (PC-C-6′), 140.1 (PC-C-11′), 139.5 (PC-C-14′), 139.4 (PC-C-3′), 136.3 (Ph-C), 136.1, 
134.5 (Ar-C), 133.3, 133.0, 132.9, 132.7 (PC-CH), 132.5 (Ar-C), 132.4 (PC-C-4′), 131.9, 131.6, 129.9, 
129.0, 128.6, 128.5, 128.1 (Ar-CH), 127.9, 127.8, 127.3 (PC-CH), 126.8 (Ph-CH), 126.6 (Ph-2CH), 126.2, 
126.1 (Ph-CH), 106.2 (thiazole-CH), 50.2 (CH2Ph), 35.1 (PC-CH2-1′), 34.9 (PC-CH2-10′), 34.7 (PC-CH2-
9′), 34.6 (PC-CH2-2′). IR (ATR, cm−1) ṽ = 3254–3060 (w, NH), 2930 (w, Ar-CH), 2870 (w, aliph-CH) 
1690 (s, CO), 1566 (s, C=N). MS (ESI) m/z (%) = 566.2 [M]+ (100). HRMS (ESI, [M]+, [C37H32ON332S1]+) 
Calc.: 566.2261, Found: 566.2246. 
3.1.11. 3-Allyl-2-(2-(4′-[2.2]Paracyclophonyl)hydrazineyl)-4-(naphth-2-yl)-thiazol-3-ium Bromide 
(8c) 
Colorless crystal (ethanol), yield: 0.430 g (72%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 11.23 
(s, 1H, amide-NH), 8.20 (s, 1H, Ar-H), 8.12–8.02 (m, 3H, Ar-H), 7.70–7.63 (m, 3H, Ar-H), 7.35 (s, 1H, 
thiazole-CH), 6.95 (s, 1H, NH), 6.79–6.63 (m, 3H, PC-H), 6.62–6.51 (m, 4H, PC-H), 5.89–5.80 (m, 1H, 
allyl-CH=), 5.32–5.00 (m, 2H, allyl-CH2), 4.84–4.70 (m, 2H, allyl-CH2=), 3.73–3.67 (m, 1H, PC-CH2), 
3.22–2.93 (m, 7H, PC-CH2). 13C NMR (100 MHz, DMSO-d6, ppm) δ = 173.8 (amide-CO), 168.2 
(thiazole-C2), 143.4 (thiazole-C4), 141.5 (PC-C-6′), 141.1 (PC-C-11′), 140.4 (PC-C-14′), 140.3 (PC-C-3′), 
137.3, 137.2 (Ar-C), 134.4, 133.9, 133.8, 133.6 (PC-CH), 133.6 (Ar-C), 133.5 (allyl-CH=), 133.4, 132.4, 
132.2, 131.1, 130.9, 129.7, 129.5 (Ar-CH), 128.9 (PC-C-4′), 128.3, 127.2, 126.6 (PC-CH), 118.9 (allyl-
CH2=), 108.3 (thiazole-CH), 50.4 (allyl-CH2), 36.0 (PC-CH2-1′), 35.8 (PC-CH2-10′), 35.6 (PC-CH2-9′), 
35.5 (PC-CH2-2′). IR (ATR, cm−1) ṽ = 3255–3029 (w, NH), 3003–2866 (w, Ar-CH), 2819 (m, aliph-CH) 
1683 (s, CO), 1581 (s, C=N). MS (ESI) m/z (%) = 516.2 [M]+ (100). HRMS (ESI, [M]+, [C33H30ON332S1]+) 
Calc.: 516.2104, Found: 516.2091. 
3.1.12. 2-(2-(4′-[2.2]Paracyclophonyl)hydrazineyl)-3-ethyl-4-(naphth-2-yl)-thiazol-3-ium Bromide 
(8d) 
Colorless crystal (ethanol), yield: 0.305 g (52%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 11.20 
(s, 1H, amide-NH), 8.25 (s, 1H, Ar-H), 8.15–8.06 (m, 3H, Ar-H), 7.75–7.66 (m, 3H, Ar-H), 7.27 (s, 1H, 
thiazole-CH), 6.95 (s, 1H, NH), 6.77 (dd, J = 7.8, 1.8 Hz, 1H, PC-H), 6.66–6.53 (m, 6H, PC-H), 4.10 (q, 
J = 7.2 Hz, 2H, ethyl-CH2), 3.73–3.68 (m, 1H, PC-CH2), 3.22–2.94 (m, 7H, PC-CH2), 1.23 (t, J = 7.1 Hz, 
3H, ethyl-CH3). 13C NMR (100 MHz, DMSO-d6, ppm) δ = 173.3 (amide-CO), 167.5 (thiazole-C2), 
142.2 (thiazole-C4), 140.5 (PC-C-6′), 140.2 (PC-C-11′), 139.5 (PC-C-14′), 139.4 (PC-C-3′), 136.4, 136.3 
(Ar-C), 133.5, 133.0, 132.9, 132.7 (PC-CH), 132.6 (Ar-C), 132.5, 131.5, 131.4, 130.3, 128.9, 128.6, 128.0 
(Ar-CH), 127.9 (PC-C-4′), 127.4, 126.5, 125.9 (PC-CH), 107.3 (thiazole-CH), 43.1 (ethyl-CH2), 35.1 
(PC-CH2-1′), 34.9 (PC-CH2-10′), 34.7 (PC-CH2-9′), 34.6 (PC-CH2-2′), 13.1 (ethyl-CH3). IR (ATR, cm−1) ṽ 
= 3264–3012 (w, NH), 3012 (w, Ar-CH), 2927–2744 (m, aliph-CH) 1683 (s, CO), 1584 (s, C=N). MS 
(ESI) m/z (%) = 504.2 [M]+ (100). HRMS (ESI, [M]+, [C32H30ON332S1]+) Calc.: 504.2104, Found: 504.2088. 
3.1.13. 3-(4′-[2.2]Paracyclophan)amido-2-(cyclopropylamino)-4-(naphth-2-yl)thiazol-3-ium Bromide 
(9) 
Colorless crystal (ethanol), yield: 0.300 g (60%). 1H NMR (400 MHz, DMSO-d6, ppm) δ = 11.79 
(s, 1H, amide-NH), 8.45 (s, 1H, Ar-H), 8.28–8.01 (m, 3H, Ar-H), 7.89–7.61 (m, 3H, Ar-H), 7.47 (s, 1H, 
thiazole-CH), 6.92–6.60 (m, 3H, PC-H), 6.52–6.26 (m, 4H, PC-H), 5.36 (s, 1H, NH), 3.72–3.66 (m, 1H, 
PC-CH2), 3.19–2.78 (m, 7H, PC-CH2), 2.74–2.64 (m, 1H, cyclopropyl-CH), 1.04–0.95 (m, 2H, 
cyclopropyl-CH2), 0.81–0.75 (m, 2H, cyclopropyl-CH2). 13C NMR (100 MHz, DMSO-d6, ppm) δ = 
172.0 (amide-CO), 166.1 (thiazole-C2), 142.4 (thiazole-C4), 142.3 (PC-C-6′), 139.7 (PC-C-11′), 139.5 
(PC-C-14′), 138.8 (PC-C-3′), 137.1, 136.6 (Ar-C), 136.4, 134.1, 133.2, 132.9 (PC-CH), 132.7 (Ar-C), 
131.8, 130.3, 129.9, 129.1, 128.8, 128.4, 127.9 (Ar-CH), 127.4 (PC-C-4′), 126.9, 126.3, 126.1 (PC-CH), 
104.3 (thiazole-CH), 35.0 (PC-CH2-1′), 34.8 (PC-CH2-10′), 34.6 (PC-CH2-9′), 34.5 (PC-CH2-2′), 28.2 
(cyclopropyl-CH), 7.3 (cyclopropyl-CH2), 7.2 (cyclopropyl-CH2). IR (ATR, cm−1) ṽ = 3260–3043 (w, 
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NH), 3015–2886 (w, Ar-CH), 2819 (m, aliph-CH) 1679 (CO), 1588 (C=N). MS (ESI) m/z (%) = 516.2 
[M]+ (65). HRMS (ESI, [M]+, [C33H30ON332S1]+) Calc.: 516.2104, Found: 516.2155. 
3.1.14. Crystal Structure Determinations of 3e, 8c, and 9 
The single-crystal X-ray diffraction studies were carried out on a Bruker D8 Venture 
diffractometer with PhotonII detector at 123(2) K using Cu-Kα radiation (INCOATEC microfocus 
sealed tube ,λ = 1.54178 Å, Middlesex County, MA, USA). Dual-space methods (SHELXT) [38] were 
used for structure solution, and refinement was carried out using SHELXL-2014 (full-matrix lowest-
squares on F2) [39]. Hydrogen atoms were localized by difference electron density determination 
and refined using a riding model (H(N, O)-free). Semi-empirical absorption corrections were 
applied. For 3e, an extinction correction was/were applied. The absolute structure of 8c was 
determined by refinement of the Parsons x-parameter [41] 
3e: red crystals, C31H25N3O3S·0.625(CH4O)·0.375(C2H6O), Mr = 556.90, crystal size 0.16 × 0.06 × 
0.03 mm, monoclinic, space group P21/c (No. 14), a = 7.2104(3) Å, b = 14.3984(6) Å, c = 26.4331(12) Å, 
β = 97.291(2)°, V = 2722.0(2) Å3, Z = 4, ρ = 1.359 Mg/m−3, µ(Cu-Kα) = 1.428 mm−1, F(000) = 1172, 2θmax = 
140-2°, 51,610 reflections, of which 5279 were independent (Rint = 0.039), 367 parameters, 43 
restraints, R1 = 0.058 (for 5006 I > 2σ(I)), wR2 = 0.175 (all data), S = 1.10, largest diff. peak/hole = 0.40/-
0.44 e Å−3. The structure was refined as a 2-component twin. There is a solvent disorder (MeOH vs. 
EtOH). In addition, the methylene moieties in C2H4-bridges were disordered (see the cif-file for 
details). 
8c: colorless crystals, C33H30N3OS·Br, Mr = 596.57, crystal size 0.20 × 0.06 × 0.02 mm, 
orthorhombic, space group Pna21 (No. 33), a = 17.5892(5) Å, b = 25.1597(7) Å, c = 12.9433(4) Å, V = 
5727.9(3) Å3, Z = 8, ρ = 1.384 Mg/m−3, µ(Cu-Kα) = 2.87 mm−1, F(000) = 2464, 2θmax = 144.4°, 43,557 
reflections, of which 10,648 were independent (Rint = 0.028), 698 parameters, 94 restraints, R1 = 0.033 
(for 10,402 I > 2σ(I)), wR2 = 0.083 (all data), S = 1.07, largest diff. peak/hole = 0.64/-0.53 e Å−3, x = -
0.017(6). One naphthalene moiety was disordered (see the cif-file for details). 
9: colorless crystals, C33H30N3OS·Br, Mr = 596.57, crystal size 0.08 × 0.04 × 0.01 mm, monoclinic, 
space group P21/c (No. 14), a = 16.9166(12) Å, b = 9.1979(6) Å, c = 18.6636(12) Å, β = 102.929(4)°, V = 
2830.4(3) Å3, Z = 4, ρ = 1.400 Mg/m−3, µ(Cu-Kα) = 2.92 mm−1, F(000) = 1232, 2θmax = 144.4°, 22,667 
reflections, of which 5534 were independent (Rint = 0.152), 359 parameters, 2 restraints, R1 = 0.078 
(for 2904 I > 2σ(I)), wR2 = 0.271 (all data), S = 1.01, largest diff. peak/hole = 0.59/-0.51 e Å3. 
CCDC-1998918 (3e), 1998919 (8c), and 1998920 (9) contained the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
3.2. Biological Evaluation 
3.2.1. Sixty Cancer Cell Lines Screening at the NCI 
The NCI anticancer screening methodology has been described elsewhere in detail at 
https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm. A summary of the 
experimental assay methodology is found in the Supplementary Data. 
3.2.2. Cytotoxic Activity Using the MTT Assay and Evaluation of IC50 
MTT assay was performed to investigate the effect of the synthesized compounds on 
melanoma SK-MEL-5 to explore the antiproliferative potential of the compounds. MTT assay was 
performed according to the reported data [42] (see Supplementary Data). 
3.2.3. CDK Inhibitory Assay 
A cell-free assay was used to explore the mechanism of inhibition of the CDK kinase of the 
most active compound according to the reported method (see Supplementary Data). 
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3.2.4. Cell Cycle and Annexin-V FITC Apoptotic Study 
Generally, the Annexin V-FITC/PI (fluorescein-isothiocyanate/propidium iodide) Apoptosis 
Detection Kit (ab#139418) (BioVision Research Products, 980 Linda Vista Avenue, MountainView, 
CA, 94043, USA) was used for the apoptosis assay according to the manufacturer’s instructions. 
Firstly, NCI-H522 cells (4 × 106 cells/well) were incubated with compound 3c (at conc. IC50 = 0.81 
μM) for 24 h. A control experiment (with untreated NCI-H522 cells) was carried out for 
comparison. Cells were washed three times with ice-cold PBS, resuspended in PBS, and then 
stained for 15 min with 5-mL annexin V-FITC and 5-mL PI binding buffer in a dark place at ambient 
temperature. Finally, the BD FACS CALIBER flow cytometer was used for the analysis of stained 
cells and the measurement of the extent of apoptosis [43]. 
3.2.5. Inhibition of Phospho-CDK1/CDC2 Cell-Based Phosphorylation in SK-MEL-5 Cancer Cells 
The Colorimetric Cell-Based ELISA Kit (Durham, NC, USA) allowed for the qualitative 
determination of the target protein concentration achieved by an indirect ELISA format [44] (see 
Supplementary Data). 
3.2.6. Caspase-3 Activation Assay 
Cell line cells of SK-MEL-5 were obtained from ATCC Camarillo, CA 93012, USA. RPMI 1640 
containing 10% FBS was used to allow cells to grow at 37 °C and stimulated with the compounds to 
be tested for caspase-3 [45] (see Supplementary Data). 
3.2.7. Docking Study 
A molecular docking study was performed for the most active synthesized compounds with 
CDK1. The docking of compounds 3a–e, 8a–d, 9, and Dinaciclib was carried out using 
AutoDock4.2.6 software [46]. Target compounds were constructed, and their 3D structures were 
generated using Omega2 software [47,48]. Energy minimization was performed for the generated 
conformations by the MMFF94S force field using SZYBKI [49]. The partial charges were calculated 
using the Gasteiger method [50] X-ray. The crystallographic structure of the CDK1 in complex with 
Dinaciclib (PDB code: 6GU6 [51]) was downloaded from the Protein Data Bank (www.rcsb.org) and 
prepared for docking calculations by deleting the heteroatoms and adding hydrogen atoms with 
the help of the H++ server [52]. The AutoDock protocol was followed to prepare the pdbqt file for 
the receptor [53]. The receptor was fixed, and docking of the designed compounds was done into 
the catalytic site of the CDK1 enzyme. The maximum number of energy evaluations (eval) was set 
to 25,000,000, and the number of genetic algorithm (GA) runs was set to 250. The grid with a size of 
60 Å × 60 Å × 60 Å was positioned at the center of the active site. The predicted binding poses for 
each compound were processed by the built-in clustering analysis (1.0 Å RMSD tolerance), with the 
conformation of the lowest energy with respect to the largest cluster selected as the representative. 
3.2.8. Statistical Analysis 
The experimental results were quantified by GraphPad Prism 5 (Version 5.0, GraphPad 
Software, La Jolla, CA, USA). Comparisons between treatments were analyzed by a one-way 
ANOVA (and nonparametric) tests. p-values were labeled in the figures, and standard error of the 
mean was also shown. 
4. Conclusion 
In the current study, a novel three-series assembly of three bioactive entities: 1,4-
dihydronaphthoquinone, thiazole, and [2.2]paracyclophane derivative in solid hybrid structures 
were synthesized and characterized. One-dose anticancer test results indicated that compounds 3a–
e exhibited the highest ability to inhibit the proliferation of different cancer cell lines. An in vitro 
five-dose full NCI 60-cell panel assay revealed that compounds 3c–e exhibited a broad-spectrum 
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antitumor activity against the nine tumor subpanels tested without pronounced selectivity. 
Compounds 3a–e exhibited the potent inhibition of melanoma SK-MEL-5 cancer cell growth 
compared to Dinaciclib as a reference. Compound 3c showed the lowest IC50 of 54.8 nM on the 
target enzyme CDK1 in comparison to Dinaciclib as a reference. Accordingly, compound 3c was 
extensively investigated and showed a marked downregulation of phospho-Tyr15 with a level (7.45 
pg/mL) comparable to the reference. Furthermore, the effect of compound 3c on caspase-3 was 
evaluated and found to increase in its level by 8.66-fold. The effect of compound 3c on the cell cycle 
arrest was also examined. Moreover, a molecular docking study was performed to explain the 
binding mode and affinity of the synthesized compounds. These results led to the discovery of 
promising novel hybrids of interesting thiazole/paracyclophanes as a starting point in the medicinal 
chemistry art that warrant further research and development as potential cancer candidates. 
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spectrum of compound 3a. Figure S4. HRMS spectrum of compound 3a. Figure S5. 1H NMR spectrum of 
compound 3b. Figure S6. 13C NMR spectrum of compound 3b. Figure S7. Mass spectrum of compound 3b. 
Figure S8. HRMS spectrum of compound 3b. Figure S9. 1H NMR spectrum of compound 3c. Figure S10. 13C 
NMR spectrum of compound 3c. Figure S11. Mass spectrum of compound 3c. Figure S12. HRMS spectrum of 
compound 3c. Figure S13. 1H NMR spectrum of compound 3d. Figure S14. 13C NMR spectrum of compound 
3d. Figure S15. Mass spectrum of compound 3d. Figure S16. HRMS spectrum of compound 3d. Figure S17. 1H 
NMR spectrum of compound 3e. Figure S18. 13C NMR spectrum of compound 3e. Figure S19. Mass spectrum 
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spectrum of compound 8d. Figure S33. 1H NMR spectrum of compound 9. Figure S34. 13C NMR spectrum of 
compound 9. Figure S35. HRMS and Mass spectrum of compound 8a. 2. Biology Table S1. DNA content % 
using propidium iodide flow cytometry. Results Significantly different from control at *** p < 0.05. Table S2. 
Predicted binding scores for compounds 3a-e, 8a-d, 9 and Dinacicilib in CDK1 active site (PDB code: 6GU6).  
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6GU6).  Figure S36. Dose Response Curves for all cell line for compound 3d. Figure S37. Log 10 concentration 
of compound 10d. Figure S38. Log 10 concentration of compound 3d. Figure S39. Dose Response Curves for all 
cell line for compound 3d. Figure S40. Log 10 concentration of compound 3e. Figure S41. Log 10 concentration 
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